pI: 6.3827 |
Length (AA): 390 |
MW (Da): 41656 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
1 | 370 | 4lmp (A) | 1 | 371 | 44.00 | 0 | 1 | 1.57122 | -0.93 |
1 | 371 | 2eez (A) | 1 | 369 | 55.00 | 0 | 1 | 1.56078 | -0.5 |
1 | 358 | 1pjc (A) | 1 | 357 | 51.00 | 0 | 1 | 1.58965 | -0.76 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | ME49 Oocyst. | Fritz HM |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | ME49 merozoite. | Hehl AB |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | VEG Tachyzoite, ME49 Tachyzoite, ME49 Bradyzoite. | Gregory Sibley/Greg |
Gregory | ToxoDB |
Fritz HM | Transcriptomic analysis of toxoplasma development reveals many novel functions and structures specific to sporozoites and oocysts. |
Sibley/Greg | ToxoDB |
Hehl AB | Asexual expansion of Toxoplasma gondii merozoites is distinct from tachyzoites and entails expression of non-overlapping gene families to attach, invade, and replicate within feline enterocytes. |
Ortholog group members (OG5_127241)
Species | Accession | Gene Product |
---|---|---|
Caenorhabditis elegans | CELE_C15H9.1 | Protein NNT-1 |
Cryptosporidium hominis | Chro.10120 | NAD(P) transhydrogenase beta subunit |
Cryptosporidium hominis | Chro.80274 | transhydrogenase 7B2 |
Cryptosporidium parvum | cgd1_990 | pyridine nucleotide/ NAD(P) transhydrogenase alpha plus beta subunits, duplicated gene, 12 transmembrane domain |
Cryptosporidium parvum | cgd8_2330 | pyridine nucleotide/ NAD(P) transhydrogenase alpha plus beta subunits, duplicated gene, possible signal peptide plus 12 transmem |
Dictyostelium discoideum | DDB_G0269046 | NAD+ transhydrogenase |
Escherichia coli | b1603 | pyridine nucleotide transhydrogenase, alpha subunit |
Escherichia coli | b1602 | pyridine nucleotide transhydrogenase, beta subunit |
Echinococcus granulosus | EgrG_000591000 | nadp transhydrogenase |
Entamoeba histolytica | EHI_055400 | NAD(P)( ) transhydrogenase (AB-specific), alpha subunit, putative |
Entamoeba histolytica | EHI_014030 | NAD(P) transhydrogenase subunit alpha, putative |
Entamoeba histolytica | EHI_060020 | NAD(P) transhydrogenase beta subunit, putative |
Echinococcus multilocularis | EmuJ_000591000 | nadp transhydrogenase |
Homo sapiens | ENSG00000112992 | nicotinamide nucleotide transhydrogenase |
Mycobacterium leprae | ML1532 | SECRETED L-ALANINE DEHYDROGENASE ALD (40 KDA ANTIGEN) (TB43) |
Mycobacterium leprae | ML2636c | PROBABLE NAD(P) TRANSHYDROGENASE (SUBUNIT ALPHA) PNTAA [FIRST PART; CATALYTIC PART] (PYRIDINE NUCLEOTIDE TRANSHYDROGENASE SUBUNI |
Mycobacterium leprae | ML2634c | PROBABLE NAD(P) TRANSHYDROGENASE (SUBUNIT BETA) PNTB [INTEGRAL MEMBRANE PROTEIN] (PYRIDINE NUCLEOTIDE TRANSHYDROGENASE SUBUNIT B |
Mus musculus | ENSMUSG00000025453 | nicotinamide nucleotide transhydrogenase |
Mycobacterium tuberculosis | Rv2780 | Secreted L-alanine dehydrogenase Ald (40 kDa antigen) (TB43) |
Mycobacterium tuberculosis | Rv0155 | Probable NAD(P) transhydrogenase (subunit alpha) PntAa [first part; catalytic part] (pyridine nucleotide transhydrogenase subuni |
Mycobacterium tuberculosis | Rv0157 | Probable NAD(P) transhydrogenase (subunit beta) PntB [integral membrane protein] (pyridine nucleotide transhydrogenase subunit b |
Mycobacterium ulcerans | MUL_2154 | secreted L-alanine dehydrogenase Ald (40 kDa antigen) |
Mycobacterium ulcerans | MUL_4735 | NAD(P) transhydrogenase PntA |
Mycobacterium ulcerans | MUL_4733 | NAD(P) transhydrogenasePntB |
Neospora caninum | NCLIV_012720 | NAD(P) transhydrogenase, beta subunit, related |
Neospora caninum | NCLIV_058000 | alanine dehydrogenase, putative |
Plasmodium berghei | PBANKA_1317200 | pyridine nucleotide transhydrogenase, putative |
Plasmodium falciparum | PF3D7_1453500 | pyridine nucleotide transhydrogenase, putative |
Plasmodium knowlesi | PKNH_1228600 | pyridine nucleotide transhydrogenase, putative |
Plasmodium vivax | PVX_117805 | pyridine nucleotide transhydrogenase, putative |
Plasmodium yoelii | PY05907 | NAD(P) transhydrogenase beta subunit, putative |
Schistosoma japonicum | Sjp_0011150 | ko:K00324 NAD(P) transhydrogenase subunit alpha [EC1.6.1.2A], putative |
Schistosoma japonicum | Sjp_0134090 | NAD(P) transhydrogenase subunit alpha, putative |
Schistosoma mansoni | Smp_082370 | NADP transhydrogenase |
Schmidtea mediterranea | mk4.006034.00 | |
Schmidtea mediterranea | mk4.003173.00 | NAD(P) transhydrogenase, mitochondrial |
Schmidtea mediterranea | mk4.011090.00 | NAD(P) transhydrogenase, mitochondrial |
Schmidtea mediterranea | mk4.011090.03 | |
Schmidtea mediterranea | mk4.006604.00 | NAD(P) transhydrogenase, mitochondrial |
Toxoplasma gondii | TGME49_315260 | alanine dehydrogenase |
Toxoplasma gondii | TGME49_301210 | NAD(P) transhydrogenase subunit beta, putative |
Trichomonas vaginalis | TVAG_445130 | nADP transhydrogenase, putative |
Trichomonas vaginalis | TVAG_235800 | nADP transhydrogenase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
mtu2827 | Mycobacterium tuberculosis | non-essential | nmpdr |
mtu158 | Mycobacterium tuberculosis | non-essential | nmpdr |
b1602 | Escherichia coli | non-essential | goodall |
b1603 | Escherichia coli | non-essential | goodall |
PBANKA_1317200 | Plasmodium berghei | Dispensable | plasmo |
TGME49_301210 | Toxoplasma gondii | Essentiality uncertain | sidik |
TGME49_315260 this record | Toxoplasma gondii | Essentiality uncertain | sidik |
TGME49_301210 | Toxoplasma gondii | Probably non-essential | sidik |
TGME49_315260 this record | Toxoplasma gondii | Probably non-essential | sidik |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.